Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

Multi-target TMS for Schizophrenia Negative Symptoms

NCT: NCT07559084 · NOT_YET_RECRUITING

NCT IDNCT07559084
StatusNOT_YET_RECRUITING
Start Date2026-10-01
Completion2028-01-30
SponsorShanghai Mental Health Center (OTHER)
First posted
Last updated

Brief Summary

This randomized controlled trial (RCT) is the first to evaluate the efficacy and safety of a multi-target TMS protocol targeting the right orbitofrontal cortex (R-OFC), left dorsolateral prefrontal cortex (L-DLPFC), and left inferior parietal lobule (L-IPL) for negative symptoms of schizophrenia.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.

↑